Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: A randomised controlled trial

Lancet

Volumn 360, Issue 9326, 2002, Pages 47-53

  Oldfield, W L G ^a   Larche M ^a   Kay, A B ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; FEL D 1 PEPTIDE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ALLERGIC REACTION; ARTICLE; ASTHMA; CAT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; MALE; PEPTIDE SYNTHESIS; PRICK TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

EID: 0037031090     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09332-7     Document Type: Article

References (21)

1. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d 1
2. Treatment of cat allergy with T-cell reactive peptides
3. The safety and efficacy of ALLERVAX CAT in cat allergic patients
4. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats
5. Fel d 1 peptides: Effect on skin tests and cytokine synthesis in cat-allergic human subjects
6. IgE-independent MHC-restricted T cell peptide epitope-induced late asthmatic reactions
7. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects
8. Long-term clinical efficacy of grass-pollen immunotherapy
9. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses
10. Allergy and allergic diseases. First of two parts
11. A dosing protocol of allergen-derived T cell peptide epitopes for the treatment of allergic disease
12. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy
13. Inhibition of IgE-induced activation of human mast cells by interleukin-10
14. Grass pollen immunotherapy decreases the number of mast cells in the skin
15. An intracellular calcium increase and protein kinase C activation fail to initiate T cell proliferation in the absence of a costimulatory molecule
16. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes
17. A critical role for transforming growth factor-β but not IL-4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells
18. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
19. Transforming growth factor beta (TGF-β)-dependent inhibition of T helper cell 2 (Th2)-induced autoimmunity by self-major histocompatibility complex (MHC) class II-specific, regulatory CD4(+) T cell lines
20. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom
21. Role of interleukin-10 in specific immunotherapy